Strativa Pharmaceuticals
300 Tice Boulevard
Woodcliff Lake
New Jersey
07677
United States
Tel: 201-802-4200
21 articles about Strativa Pharmaceuticals
-
FDA Green Lights Strativa Pharmaceuticals' Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device
6/11/2014
-
John A. MacPhee Resigns From Strativa Pharmaceuticals
12/17/2010
-
Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal(R)
10/26/2010
-
BioAlliance Pharma Announces the Launch of Oravig(R) on the US Market by Its Commercial Partner, Strativa Pharmaceuticals/Par Pharmaceutical, Inc.
8/24/2010
-
FDA Approves Strativa Pharmaceuticals' Zuplenz(R) (ondansetron) Oral Soluble Film
7/6/2010
-
FDA Approves Strativa Pharmaceuticals's Oravig(TM) Buccal Tablets for Treatment of Oropharyngeal Candidiasis
4/16/2010
-
Strativa Pharmaceuticals Says FDA Declines Nausea Drug Approval; FDA Citing Travel Restrictions to India
2/8/2010
-
MonoSolRx LLC and Strativa Pharmaceuticals Extend Strategic Relationship
1/5/2010
-
Strativa Pharmaceuticals' Development Partner, BioAlliance Pharma, Presents Phase III Study
9/15/2009
-
Strativa Pharmaceuticals's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
6/16/2009
-
Strativa Pharmaceuticals's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
6/10/2009
-
Strativa Pharmaceuticals Provides Product Pipeline Update
4/9/2009
-
MonoSolRx LLC and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
4/9/2009
-
Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical; QOL Medical to Receive $54.5 Million
4/1/2009
-
Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
12/2/2008
-
MonoSolRx LLC Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals
6/17/2008
-
Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
5/29/2008
-
Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
4/22/2008
-
Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Inc., Announces the Discontinuation of the Development Program for Pafuramidine
2/25/2008
-
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell
1/15/2008